Drug Profile

Abametapir - Hatchtech

Alternative Names: BRN-0123183; DeOvo Lotion; DFD-11; HA-44; Ha44; Ha44 Gel; Xeglyze Lotion

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hatchtech
Developer Dr Reddys Laboratories; Hatchtech
Class Antiparasitics; Heterocyclic compounds; Pyridines; Small molecules
Mechanism of Action Chelating agents; Metalloprotease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Registered Pediculosis

Most Recent Events

05 Jan 2026 Pelthos Therapeutics acquires Abametapir from Hatchtech
05 Jan 2026 Pelthos Therapeutics plans to relaunch abametapir for Pediculosis in the first half of 2027 (topical)
27 Jul 2020 Registered for Pediculosis (In adolescents, In children, In infants, In adults) in USA (Topical)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com